The positive preclinical results for HT-ALZ, a treatment for Alzheimer's disease, indicate potential success in further development and eventual commercialization. This news directly impacts Hoth Therapeutics' share price, as it demonstrates progress in their product pipeline and increases investor confidence in the company's potential.